West Pharmaceutical Services, Inc. (BVMF:W2ST34)
Brazil
· Delayed Price · Currency is BRL 34.50
-0.30 (-0.86%)
At close: Feb 3, 2026
BVMF:W2ST34 Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | 493.7 | 492.7 | 593.4 | 585.9 | 661.8 | Upgrade
|
| Depreciation & Amortization | 171.4 | 155.4 | 137.3 | 120.6 | 122.3 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | 11.6 | - | - | Upgrade
|
| Asset Writedown & Restructuring Costs | 17.1 | 7.3 | 9.6 | 21.5 | 5.6 | Upgrade
|
| Loss (Gain) on Equity Investments | -10.5 | -13.4 | -14.3 | -18.1 | -17.4 | Upgrade
|
| Stock-Based Compensation | 23.8 | 18.7 | 23.3 | 23.7 | 37.5 | Upgrade
|
| Other Operating Activities | -20.5 | -10.2 | 36 | 5.4 | -27.7 | Upgrade
|
| Change in Accounts Receivable | 6.9 | -58.8 | 4 | -35.6 | -123.5 | Upgrade
|
| Change in Inventory | -62.8 | 42 | -13.5 | -49.8 | -86.5 | Upgrade
|
| Change in Accounts Payable | 17.9 | 2.9 | 4.4 | -2.8 | 16.8 | Upgrade
|
| Change in Other Net Operating Assets | 117.8 | 16.8 | -15.3 | 73.2 | -4.9 | Upgrade
|
| Operating Cash Flow | 754.8 | 653.4 | 776.5 | 724 | 584 | Upgrade
|
| Operating Cash Flow Growth | 15.52% | -15.85% | 7.25% | 23.97% | 23.60% | Upgrade
|
| Capital Expenditures | -285.9 | -377 | -362 | -284.6 | -253.4 | Upgrade
|
| Cash Acquisitions | - | - | - | - | -2.2 | Upgrade
|
| Other Investing Activities | - | -1.7 | -6.7 | -3.6 | 2.5 | Upgrade
|
| Investing Cash Flow | -285.9 | -378.7 | -368.7 | -288.2 | -253.1 | Upgrade
|
| Long-Term Debt Issued | - | 164.7 | - | - | - | Upgrade
|
| Total Debt Issued | - | 164.7 | - | - | - | Upgrade
|
| Long-Term Debt Repaid | -1.1 | -192.3 | -2.4 | -44.3 | -2.2 | Upgrade
|
| Total Debt Repaid | -1.1 | -192.3 | -2.4 | -44.3 | -2.2 | Upgrade
|
| Net Debt Issued (Repaid) | -1.1 | -27.6 | -2.4 | -44.3 | -2.2 | Upgrade
|
| Issuance of Common Stock | 18.2 | 32.7 | 51 | 28.2 | 37.1 | Upgrade
|
| Repurchase of Common Stock | -136.8 | -566.6 | -451.2 | -222.2 | -151.9 | Upgrade
|
| Common Dividends Paid | -61.2 | -59.1 | -57 | -54.1 | -51.1 | Upgrade
|
| Other Financing Activities | -4.2 | -2 | - | -1.2 | - | Upgrade
|
| Financing Cash Flow | -185.1 | -622.6 | -459.6 | -293.6 | -168.1 | Upgrade
|
| Foreign Exchange Rate Adjustments | 22.9 | -21.4 | 11.4 | -10.5 | -15.7 | Upgrade
|
| Net Cash Flow | 306.7 | -369.3 | -40.4 | 131.7 | 147.1 | Upgrade
|
| Free Cash Flow | 468.9 | 276.4 | 414.5 | 439.4 | 330.6 | Upgrade
|
| Free Cash Flow Growth | 69.64% | -33.32% | -5.67% | 32.91% | 10.90% | Upgrade
|
| Free Cash Flow Margin | 15.25% | 9.55% | 14.05% | 15.22% | 11.68% | Upgrade
|
| Free Cash Flow Per Share | 6.45 | 3.75 | 5.50 | 5.80 | 4.33 | Upgrade
|
| Cash Interest Paid | 0.3 | 0.5 | 6 | 6.6 | 8 | Upgrade
|
| Cash Income Tax Paid | 125.2 | 71.4 | 90.8 | 109.7 | 171.8 | Upgrade
|
| Levered Free Cash Flow | 273.88 | 206.73 | 196.35 | 246.54 | 210.05 | Upgrade
|
| Unlevered Free Cash Flow | 274.19 | 208.6 | 201.98 | 251.48 | 215.18 | Upgrade
|
| Change in Working Capital | 79.8 | 2.9 | -20.4 | -15 | -198.1 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.